Kreuter A, Wieland U, Gambichler T, Altmeyer P, Pfister H, Tenner-Racz K, Racz P, Potthoff A, Brockmeyer N H
Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany.
Br J Dermatol. 2007 Sep;157(3):523-30. doi: 10.1111/j.1365-2133.2007.08004.x. Epub 2007 Jun 15.
Human papillomavirus (HPV)-associated anogenital cancers and their precursor lesions occur in excess in human immunodeficiency virus (HIV)-infected patients despite the initiation of highly active antiretroviral therapy. In this context, a drastically increased relative risk for anal intraepithelial neoplasia (AIN) exists in HIV-infected men having sex with men (MSM). In a pilot study, imiquimod, a topical immune response modifier, has been reported to be beneficial in the treatment of AIN.
To investigate the role of several biomarkers as potential adjuncts in the course of imiquimod treatment for AIN, and to determine whether these markers correlate with the course of high-risk HPV DNA load during imiquimod therapy.
Immunohistochemical staining was performed for p16(ink4a), minichromosome maintenance protein (MCM), Ki67, proliferating cell nuclear antigen (PCNA) and p21(waf1) expression before and after 16 weeks of imiquimod treatment for AIN. High-risk HPV DNA load determinations were performed by real-time polymerase chain reaction with type-specific primers and probes for HPV types 16, 18, 31 and 33.
Histopathological and virological analyses were performed in 21 HIV-infected MSM with histologically confirmed AIN. Eighteen (86%) patients had a complete histological clearance of AIN after imiquimod therapy. As previously shown, lesional high-risk HPV DNA load significantly decreased during imiquimod therapy. Moreover, a significant decline of p16(ink4a), Ki67, MCM and PCNA expression after treatment was observed, while p21(waf1) expression changed nonsignificantly after imiquimod therapy. A significant correlation between the course of high-risk HPV DNA load and p16(ink4a) expression was observed during imiquimod treatment of AIN, whereas the decline of high-risk HPV DNA load did not significantly correlate with MCM, Ki67, PCNA or p21(waf1) expression.
The significant decrease in p16(ink4a) expression in correlation with the drop of lesional high-risk HPV load suggests that p16(ink4a) may be a useful adjunct for the evaluation of treatment response in HPV-associated malignancies and their precursor lesions.
尽管开始了高效抗逆转录病毒治疗,但人乳头瘤病毒(HPV)相关的肛门生殖器癌及其前驱病变在人类免疫缺陷病毒(HIV)感染患者中仍过度发生。在这种情况下,与男性发生性关系的HIV感染男性(男同性恋者)患肛门上皮内瘤变(AIN)的相对风险急剧增加。在一项试点研究中,局部免疫反应调节剂咪喹莫特已被报道对AIN治疗有益。
研究几种生物标志物在咪喹莫特治疗AIN过程中作为潜在辅助手段的作用,并确定这些标志物是否与咪喹莫特治疗期间高危HPV DNA载量的变化过程相关。
对21例经组织学确诊为AIN的HIV感染男同性恋者在咪喹莫特治疗AIN 16周前后进行p16(ink4a)、微小染色体维持蛋白(MCM)、Ki67、增殖细胞核抗原(PCNA)和p21(waf1)表达的免疫组化染色。采用实时聚合酶链反应和针对HPV 16、18、31和33型的型特异性引物及探针进行高危HPV DNA载量测定。
对21例经组织学确诊为AIN的HIV感染男同性恋者进行了组织病理学和病毒学分析。18例(86%)患者在咪喹莫特治疗后AIN获得了完全组织学清除。如先前所示,在咪喹莫特治疗期间,病变部位高危HPV DNA载量显著下降。此外,治疗后观察到p16(ink4a)、Ki67、MCM和PCNA表达显著下降,而咪喹莫特治疗后p21(waf1)表达变化不显著。在AIN的咪喹莫特治疗期间,观察到高危HPV DNA载量变化过程与p16(ink4a)表达之间存在显著相关性,而高危HPV DNA载量的下降与MCM、Ki67、PCNA或p21(waf1)表达无显著相关性。
p16(ink4a)表达的显著下降与病变部位高危HPV载量的下降相关,提示p16(ink4a)可能是评估HPV相关恶性肿瘤及其前驱病变治疗反应的有用辅助指标。